An increasing number of studies have focused on the association between leptin, adiponectin levels and the risk as well as the prognosis of hepatocellular carcinoma. However, the reported results are conflicting. A meta-analysis was performed to assess the correlation between leptin, adiponectin levels and risk and prognosis of hepatocellular carcinoma (CRD42020195882). Through June 14, 2020, PubMed, Cochrane Library and EMBASE databases were searched, including references of qualifying articles. Titles, abstracts, and main texts were reviewed by at least 2 independent readers. Stata 16.0 was used to calculate statistical data. Thirty studies were included in this meta-analysis and results showed that hepatocellular carcinoma group had significantly higher leptin levels than the cancer-free control group (SMD = 1.83, 95% CI (1.09, 2.58), P = 0.000), the healthy control group (SMD = 4.32, 95% CI (2.41, 6.24), P = 0.000) and the cirrhosis group (SMD = 1.85, 95% CI (0.70, 3.01), P = 0.002). Hepatocellular carcinoma group had significantly higher adiponectin levels than the healthy control group (SMD = 1.57, 95% CI (0.37, 2.76), P = 0.010), but no statistical difference compared with the cancer-free control group (SMD = 0.24, 95% CI (− 0.35, 0.82), P = 0.430) and the cirrhosis group (SMD = − 0.51, 95% CI (− 1.30, 0.29), P = 0.213). The leptin rs7799039 polymorphism was associated with increased risk of hepatocellular carcinoma (G vs A: OR = 1.28, 95% CI (1.10, 1.48), P = 0.002). There were linear relationships between adiponectin levels and the risk of hepatocellular carcinoma (OR = 1.066, 95% CI (1.03, 1.11), P = 0.001). In addition, the results showed that high/positive expression of adiponectin was significantly related to lower overall survival in hepatocellular carcinoma patients (HR = 1.70, 95% CI (1.22, 2.37), P = 0.002); however, there was no significantly association between the leptin levels and overall survival (HR = 0.92, 95% CI (0.53, 1.59), P = 0.766). The study shows that high leptin levels were associated with a higher risk of hepatocellular carcinoma. Adiponectin levels were proportional to hepatocellular carcinoma risk, and were related to the poor prognosis.

中文翻译：

---

瘦素和脂联素与肝癌风险和预后的关系：传统，生存和剂量反应荟萃分析的结合

越来越多的研究集中在瘦素，脂联素水平与肝细胞癌的风险以及预后之间的关联上。但是，报告的结果是矛盾的。进行荟萃分析以评估瘦素，脂联素水平与肝细胞癌风险和预后之间的相关性（CRD42020195882）。到2020年6月14日，对PubMed，Cochrane Library和EMBASE数据库进行了搜索，包括符合条件的文章的引用。标题，摘要和主要文本由至少2位独立读者审阅。使用Stata 16.0计算统计数据。这项荟萃分析包括30项研究，结果显示，肝细胞癌组的瘦素水平明显高于无癌对照组（SMD = 1.83，95％CI（1.09，2.58），P = 0。000），健康对照组（SMD = 4.32，95％CI（2.41、6.24），P = 0.000）和肝硬化组（SMD = 1.85，95％CI（0.70，3.01），P = 0.002）。肝细胞癌组脂联素水平明显高于健康对照组（SMD = 1.57，95％CI（0.37，2.76），P = 0.010），但与无癌对照组相比无统计学差异（SMD = 0.24，95） ％CI（-0.35，0.82），P = 0.430）和肝硬化组（SMD =-0.51，95％CI（-1.30，0.29），P = 0.213）。瘦素rs7799039多态性与肝癌风险增加相关（G vs A：OR = 1.28，95％CI（1.10，1.48），P = 0.002）。脂联素水平与肝细胞癌风险之间存在线性关系（OR = 1.066，95％CI（1.03，1.11），P = 0.001）。此外，结果表明，脂联素的高/阳性表达与肝细胞癌患者的总生存率降低显着相关（HR = 1.70，95％CI（1.22，2.37），P = 0.002）；然而，瘦素水平与总生存率之间无显着相关性（HR = 0.92，95％CI（0.53，1.59），P = 0.766）。研究表明，瘦素水平高与肝细胞癌的高风险有关。脂联素水平与肝细胞癌风险成正比，并且与不良预后有关。研究表明，瘦素水平高与肝细胞癌的高风险有关。脂联素水平与肝细胞癌风险成正比，并且与不良预后有关。研究表明，瘦素水平高与肝细胞癌的高风险有关。脂联素水平与肝细胞癌风险成正比，并且与不良预后有关。